Shamburg News · 8-K filed Oct 28, 2026, 9:01 AM EDT

MetaVia to Present Phase 1 DA-1726 Data at Precision Liver Symposium 2026

MTVA · MetaVia Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: low

On October 28, 2026, MetaVia Inc. announced that an abstract highlighting Phase 1 clinical trial data for DA-1726, a dual GLP-1 and glucagon receptor agonist, was accepted for an oral presentation at the Precision Liver Symposium 2026. The presentation is scheduled for November 4, 2026, in Denver, Colorado, and is furnished under Item 7.01 and Exhibit 99.1.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001104659-26-119401.

Written from the filing by Shamburg Markets. Figures are as reported by the company.